clinical trial · NCT06454110
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
IgA NephropathyNM8074
brief summary
This is a Phase II, open-label study designed to To evaluate the safety and efficacy of NM8074 in reducing proteinuria relative to baseline in IgAN patients after 99 days of treatment.
started
Feb 1, 2028
primary completion
Dec 1, 2030
completion
Dec 1, 2031
last updated
Apr 13, 2026
detailed description
The proposed study, NM8074-IgAN-601, will enroll a planned total of 10 patients as subjects for the trial. All subjects will be administered 17 mg/kg of NM8074 intravenously every week, for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
official title
A Phase II, Open-Label Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol